Last reviewed · How we verify
NCT07073573
Evaluation of Pulpal Biomarkers in Vital Pulp Therapy
NA trial testing Vital pulp therapy in Reversible Pulpitis in 50 participants. Participants enrolled and being followed up; not accepting new ones.
25 July 2025
Quick facts
| Lead sponsor | ertuğrul karataş |
|---|---|
| Phase | NA |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 50 |
| Start date | 3 March 2025 |
| Primary completion | 25 July 2025 |
| Estimated completion | 3 August 2026 |
| Sites | 1 location across Turkey (Türkiye) |
Drugs / interventions tested
- Vital pulp therapy
Conditions studied
- Reversible Pulpitis — all drugs for Reversible Pulpitis →
- Irreversible Pulpitis — all drugs for Irreversible Pulpitis →
- Vital Pulp Therapy — all drugs for Vital Pulp Therapy →
- Dental Pulp Diseases — all drugs for Dental Pulp Diseases →
Sponsor
ertuğrul karataş
Who can join
Adults 16 to 40, any sex, with Reversible Pulpitis or Irreversible Pulpitis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This prospective clinical study aims to evaluate the association between the levels of selected pulpal biomarkers and the clinical success of vital pulp therapy in permanent teeth. Patients undergoing vital pulp therapy will be monitored over time, and biomarker expression levels will be analyzed in relation to treatment outcomes. The study intends to provide insight into the predictive value of pulp tissue biomarkers for long-term success in vital pulp procedures.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07073573
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Vital pulp therapy
Trials testing the same drug.
- NCT06903013 — Post Operative Pain Following Pulpectomy Versus Pulpotomy in Primary Molars Wit Irreversible Pulpitis · NA · not yet recruiting
- NCT05681494 — Assessment of Pain and Treatment Success After VPT Versus RCT in Mature Permanent Mandibular Molars With SIP: A RCT · NA · unknown
- NCT07261761 — Cytokines as Diagnostic Markers of Pulpal Inflammation and Their Impact on the Outcome of Vital Pulp Therapy · NA · completed
- NCT05020223 — Comparison of Sucess of Pulpotomy, Direct Pulp Capping and Indirect Pulp Capping Modalities Using MTA in Primary Teeth · NA · unknown
Other recruiting trials for Reversible Pulpitis
Currently open trials in the same condition.
- NCT07391124 — In Vivo Pulp Thermal Changes During Different Slenderization Techniques · NA · active not recruiting
- NCT06844448 — The Effect of Different Risk Factors on the Success Rate of VPT · recruiting
- NCT06433297 — Comparative Evaluation of Indirect vs. Direct Pulp Capping in Deep Carious Mandibular Molars · NA · recruiting
- NCT07101068 — Assessment of Pain and Anxiety During Infiltration Anesthesia Using Dental Anesthesia Injector Versus Conventional Syrin · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07073573 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by ertuğrul karataş
- Last refreshed: 20 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07073573.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing